ProMIS Neu­ro­sciences se­cures $20M+ PIPE; Beam Ther­a­peu­tics re­veals da­ta ahead of IND

ProMIS Neu­ro­sciences, a biotech fo­cused on de­vel­op­ing treat­ments for neu­rode­gen­er­a­tive dis­eases, closed a pri­vate in­vest­ment in pub­lic eq­ui­ty, or PIPE, that brought in $20.4 mil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.